Physicians' preferences towards coagulation factor concentrates in the treatment of haemophilia with inhibitors: A discrete choice experiment

Haemophilia

Volumn 14, Issue 3, 2008, Pages 454-465

  Lee, Won Chan ^a   Joshi, A V ^b   Woolford, S ^c   Sumner, M ^b   Brown, M ^a   Hadker, N ^a   Pashos, C L ^a  

^a ABT ASSOCIATES   (United States)

^b NOVO NORDISK INC   (United States)

^c BENTLEY COLLEGE   (United States)

Author keywords

Conjoint analysis; Factor concentrates; Haematologists; Haemophilia; Inhibitors; Preference

Indexed keywords

BLOOD CLOTTING FACTOR CONCENTRATE; BLOOD CLOTTING INHIBITOR;

ANALGESIA; ARTICLE; BLEEDING; CLINICAL DECISION MAKING; DRUG COST; DRUG INFUSION; DRUG INFUSION TIME; DRUG INFUSION VOLUME; HEMOPHILIA; HUMAN; INTERVIEW; MEDICAL PRACTICE; PATIENT CARE; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOEMBOLISM; TIME; TREATMENT RESPONSE; UNITED STATES; VIRUS INFECTION;

CHOICE BEHAVIOR; DATA INTERPRETATION, STATISTICAL; DECISION MAKING; HEMATOLOGIC AGENTS; HEMOPHILIA A; HEMOPHILIA B; HUMANS; MODELS, THEORETICAL; PHYSICIAN'S PRACTICE PATTERNS; QUESTIONNAIRES; UNITED STATES;

EID: 43149125439     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01656.x     Document Type: Article

References (30)

1. Knight C. Health economics of treating haemophilia A with inhibitors. Haemophilia 2005; 11(Suppl. 1): 11-7.
2. Soucie J, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998; 59: 288-94.
3. Lusher JM. Recombinant factor VIIa (Novoseven ®) in the treatment of internal bleeding in patients with factor VIII and IX inhibitors. Haemostasis 1996; 26(Suppl. 1): 124-30.
4. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: A systematic review. Haemophilia 2003; 9: 418-35.
5. Astermark J. Overview of inhibitors. Semin Hematol 2006; 2(Suppl. 4): S3-7.
6. Astermark J. Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia Haemophilia 2006; 12 (Suppl. 3): 52-60.
7. Knight C, Paisley S, Wight J, Jones ML. Economic modeling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
8. Ingerslev J. Hemophilia: Strategies for the treatment of inhibitor patients. Haematologica 2000; 85 (Suppl. 10): 15-20.
9. Santagostino E, Gringeri A, Mannucci PM. State of care for hemophilia in pediatric patients. Paediatr Drugs 2002; 4: 149-57.
10. Honda K, Nagao T, Kamiya T et al. Prospective matched case control study concerning the treatment and quality of life of hemophiliacs with inhibitors. Rinsho Ketsueki 1998; 39: 416-21.
11. Joshi AV, Stephens JM, Munro V et al. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors. Curr Med Res Opin 2006; 22 (1): 23-31.
12. Louviere JJ, Hensher DA, Swait JD. Stated Choice Methods, Analysis and Application. Cambridge, UK: Cambridge University Press, 2000.
13. Ryan M, Hughes J. Using conjoint analysis to assess women's preferences for miscarriage management. Health Econ 1997; 6: 261-73.
14. Ryan M. Using conjoint analysis to take account of patient preferences and go beyond health outcomes: An application to in vitro fertilization. Soc Sci Med 1999; 48: 535-46.
15. Jan S, Mooney G, Ryan M, Bruggemann K, Alexander K. The use of conjoint analysis to elicit community preferences in public health research: A case study of hospital services in South Australia. Aust N Z J Public Health 2000; 24: 64-70.
16. Mantovani LG, Monzini MS, Mannucci PM et al. Differences between patients', physicians'and pharmacists'preferences for treatment products in hemophilia: A discrete choice experiment. Haemophilia 2005; 11: 589-97.
17. Popper C. Contingent valuation of time spent on NHS waiting lists. Econ J 1990; 100: 193-9.
18. Bryan S, Buxton M, Sheldon R, Grant A. Magnetic resonance imaging for the investigation of knee injuries: An investigation of preferences. Health Econ 1998; 7: 595-603.
19. Ratcliffe J, Van Heselen R, Buxton M, Hardy K, Coletran J. Assessing patients'preferences for characteristics associated with homeopathic and conventional treatment of asthma: A conjoint analysis study. Thorax 2002; 57: 503-8.
20. Farrar S, Ryan M. Response-ordering effects: A methodological issue in conjoint analysis. Health Econ 1999; 8: 75-9.
21. Van der Pol M, Cairns J. Establishing patient preferences for blood transfusion support: An application of conjoint analysis. J Health Serv Res Policy 1998; 3: 70-6.
22. Farrar S, Ryan M, Ross D, Ludbrook A. Using discrete choice modeling in priority setting: An application to clinical service developments. Soc Sci Med 2000; 50: 63-75.
23. Ryan M, Bate A, Eastmond CJ, Ludbrook A. Use of discrete choice experiments to elicit preferences. Qual Health Care 2001; 10(Suppl. I): i55-60.
24. Louviere JJ, Eagle TC, Cohen SH Conjoint analysis: Methods, myths and much more. Center for the Study of Choice, Working Paper No. 05-001, 2005.
25. Louviere JJ, Marley AAJ. Modeling the choices of single individuals by combining efficient choice experiment designs with extra preference information. Center for the Study of Choice, Working Paper No. 04-005, 2004.
26. Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: What it can do for health care research and how to do it. Center for the Study of Choice, Working Paper No. 06-001, 2006.
27. Bierlaire M. BIOGEME: A free package for the estimation of discrete choice models. Proceedings of the 3rd Swiss Transportation Research Conference, Switzerland, Ascona, 2003.
28. Odeyemi IAO, Guest JF. Modeling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002; 5: 119-33.
29. Dundar S, Zulfikar B, Kavakli K et al. A cost evaluation of treatment alternatives in mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Turkey. J Med Econ 2005; 8: 45-54.
30. Lacey L. Economic impact of treating inhibitor patients. Pathophysiol Haemost Thromb 2002; 32 (Suppl. 1): 29-32.